SCHEMBL25734249

SCHEMBL25734249

CCOC(=O)c1ccc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)c(OCC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.42
▸ LMNA P02545 5/20 0.42
▸ TRPM8 Q7Z2W7 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALPL P05186 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CDC7 O00311 1/20 0.39
▸ DBF4 Q9UBU7 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CHRNA7 P36544 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ TRPV1 Q8NER1 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25072610 0.91 SSTR5 (0.41) MAPTLMNAALDH1A1HPGDGAA
SCHEMBL25073104 0.81 KDM4E (0.46) MAPTLMNAALDH1A1HPGDALPL
SCHEMBL25072638 0.81 MAPT (0.43) MAPTLMNATRPM8ALDH1A1HPGD
SCHEMBL25072810 0.80 POLB (0.44) MAPTLMNAALDH1A1HPGDALPL
SCHEMBL25073094 0.80 KDM4E (0.43) MAPTLMNAALDH1A1HPGDALPL
SCHEMBL25072426 0.80 HDAC6 (0.44) MAPTLMNAALDH1A1HPGDGAA
SCHEMBL25073256 0.79 MKNK1 (0.40) MAPTLMNAALDH1A1HPGDKMT2A
SCHEMBL25073055 0.79 KDM4E (0.42) MAPTLMNAALDH1A1HPGDMEN1
SCHEMBL25734381 0.78 SSTR5 (0.38) MAPTLMNAALDH1A1HPGDKMT2A
SCHEMBL25073359 0.78 L3MBTL1 (0.43) MAPTLMNAALDH1A1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 MAPT 3642/4885LMNA 2111/4885TRPM8 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback